MLTX

MoonLake Immunotherapeutics

NasdaqCMUSDEQUITY DELAYED

15.79

▼ 0.08 (0.50%)

MARKET · —

Price

Open

15.96

Prev close

15.87

Day high

16.07

Day low

15.58

Volume

1.34M

Market cap

—

P/E (TTM)

—

52W range

5.95 – 62.75

Trailing performance

Price return · vs SPY

Returnvs SPY

-4.31% -2.9%

-18.60% -22.3%

-14.67% -17.8%

-16.04% -27.1%

YTD

+19.58% +7.3%

-70.89% -90.9%

-72.55% -146.7%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

16.52

-4.41% from price

SMA 20

17.44

-9.62% from price

SMA 50

18.70

-15.71% from price

SMA 100

18.22

-13.33% from price

SMA 200

16.72

-5.72% from price

EMA 12

16.73

-5.60% from price

EMA 26

17.51

-9.83% from price

EMA 50

18.01

-12.31% from price

RSI (14)

36.1

Neutral

MACD (12,26,9)

-0.79

Hist -0.14

ATR (14)

0.85

5.41% of price

Realised vol 30D

55.5%

Annualised

Bollinger upper

19.62

20, 2σ

Bollinger lower

15.25

20, 2σ

50 / 200 cross

Golden

18.70 vs 16.72

Trend bias

Below 200

-5.72%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.12

More volatile than market

Correlation to SPY

0.12

Largely independent

Realised vol 30D

55.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-89.9%

Peak to trough

Max drawdown 5Y

-90.2%

Peak to trough

ATR 14

0.85

5.41% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 15.79

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

MLTX · links out to the publisher

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ Stocktwits · 12d ago MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals MT Newswires · 12d ago MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data Stocktwits · 19d ago Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High? Zacks · 22d ago Moonlake Immunotherapeutics Insider Sold Shares Worth $322,261, According to a Recent SEC Filing MT Newswires · 33d ago SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears Stocktwits · 41d ago MoonLake Immunotherapeutics' CFO Sells 39K Shares Motley Fool · 50d ago MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa Insider Monkey · 53d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.